Rising CA-125 but — Normal Scans — What Now?

In ovarian cancer surveillance, a progressively rising CA-125 across multiple tests is a strong signal that the disease has returned. It is not absolute — CA-125 can also rise with endometriosis, pelvic infection, liver conditions, and sometimes after surgery or a recent illness. In someone being monitored after cancer treatment, a clear upward trend is taken seriously under ESMO and NCCN guidance. A single elevated value is different from a rising trend, and your team will usually confirm the pattern with repeated tests before deciding what to do next.

Published studies and systematic reviews consistently show that FDG PET-CT identifies sites of recurrence in a meaningful proportion of patients with rising CA-125 and negative conventional imaging — and those findings often change clinical management. ESMO guidance reflects this evidence in recommending PET-CT as the next step in this specific situation. We do not quote a single percentage because rates vary by CA-125 level at the time of scanning, the original tumour subtype, and scanner quality. What matters is whether the result changes your team's next step, and for many patients in this scenario it does.

A negative PET-CT does not rule out recurrence. It means no FDG-avid deposit was visible at that moment. Disease may be present but too small, too low-grade, or in a location — such as close to the bladder — where tracer accumulation interferes with detection. Your team will typically continue surveillance with serial CA-125 measurements and repeat imaging at intervals. The decision about whether and when to start treatment with no identifiable target is a clinical judgement, sometimes made in a multidisciplinary tumour board discussion.

CT shows anatomy — the size and shape of structures. It can only distinguish a lesion from surrounding tissue if the lesion is large enough to stand out physically. FDG PET-CT adds a metabolic layer: it traces which cells are consuming glucose rapidly, and those appear as bright spots even when they are too small to register on CT alone. The PET image is then overlaid on the CT scan so your team can pinpoint the location precisely. The two scans are read together, not as separate studies.

Yes, in almost all cases. A bright deposit on PET-CT needs tissue confirmation before treatment decisions are made, because not every FDG-avid lesion is malignant — inflammation, infection, and certain benign processes also take up glucose. Your team will plan how to sample the identified site, which may be guided by ultrasound, CT, or in some cases a small surgical procedure, depending on the location and how accessible the lesion is.

Yes. CA-125 can be elevated by endometriosis, pelvic inflammatory disease, liver conditions, fluid around the lungs or abdomen, and after surgery or infection. In someone being monitored after ovarian cancer treatment, a sustained rising trend is still investigated as possible recurrence even when other explanations exist. If a specific cause — such as a recent infection — might explain a single elevated result, your team may repeat the test after it has resolved before deciding on next steps.